top of page

Free Biopharma Daily Stock Updates - 02/15/22

$XBI $95.64 | +4.2%


Covid Updates

$BNTX +5.8% BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa. source

$NRXP +1.0% NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment. source

Pipeline Updates

$MRTX -8.7% U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer source

$CTXR +5.8% Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids. source

$JAGX +6.2% Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency. source

$LEGN +2.2% Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901. source

$PDSB +1.0% PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer. source

$MBIO +6.9% Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium. source

$ACIU +3.7% AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort. source

$TGTX +9.5% TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum. source

$CYTK -6.8% Cytokinetics Announces Topline Results From METEORIC-HF. source

$CERE -3.2% Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety. source

$CALT +2.5% First patient randomized in pivotal TRANSFORM study with setanaxib. source

Business Updates

$IBRX +22.3% & $ATNX +6.8% ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility. source

$PSNL +1.4% Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection. source

$PCRX +0.7% Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022. source

$NTLA +9.1% Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer. source

$BCLI +3.0% Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®. source

$LTRN +5.1% Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio. source

$IMGN +4.7% ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion. source


Posted by FS/JM

bottom of page